Opus Genetics, Stock Shares Owned By Insiders

IRD Stock   1.03  0.01  0.96%   
Opus Genetics, fundamentals help investors to digest information that contributes to Opus Genetics,'s financial success or failures. It also enables traders to predict the movement of Opus Stock. The fundamental analysis module provides a way to measure Opus Genetics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Opus Genetics, stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Opus Genetics, Company Shares Owned By Insiders Analysis

Opus Genetics,'s Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Insiders Shares

 = 

Executives Shares

+

Employees

More About Shares Owned By Insiders | All Equity Analysis

Current Opus Genetics, Shares Owned By Insiders

    
  16.14 %  
Most of Opus Genetics,'s fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Opus Genetics, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Opus Shares Owned By Insiders Driver Correlations

Understanding the fundamental principles of building solid financial models for Opus Genetics, is extremely important. It helps to project a fair market value of Opus Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Opus Genetics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Opus Genetics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Opus Genetics,'s interrelated accounts and indicators.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition

Based on the latest financial disclosure, 16.14% of Opus Genetics, are shares owned by insiders. This is 6.32% higher than that of the Healthcare sector and 13.82% higher than that of the Biotechnology industry. The shares owned by insiders for all United States stocks is 59.96% lower than that of the firm.

Opus Shares Owned By Insiders Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Opus Genetics,'s direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Opus Genetics, could also be used in its relative valuation, which is a method of valuing Opus Genetics, by comparing valuation metrics of similar companies.
Opus Genetics, is currently under evaluation in shares owned by insiders category among its peers.

Opus Fundamentals

About Opus Genetics, Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Opus Genetics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Opus Genetics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Opus Genetics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Opus Genetics, is a strong investment it is important to analyze Opus Genetics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Opus Genetics,'s future performance. For an informed investment choice regarding Opus Stock, refer to the following important reports:
Check out Opus Genetics, Piotroski F Score and Opus Genetics, Altman Z Score analysis.
For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics,. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.09)
Revenue Per Share
0.337
Quarterly Revenue Growth
(0.68)
Return On Assets
(0.39)
Return On Equity
(0.64)
The market value of Opus Genetics, is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics,'s value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics,'s market value can be influenced by many factors that don't directly affect Opus Genetics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.